Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity (original) (raw)

• Adler AS, Lin M, Horlings H, Nuyten DS, van de Vijver MJ, Chang HY . (2006). Genetic regulators of large-scale transcriptional signatures in cancer. Nat Genet 38: 421–430.
  Article CAS PubMed PubMed Central Google Scholar
• Alessi DR, Cohen P . (1998). Mechanism of activation and function of protein kinase B. Curr Opin Genet Dev 8: 55–62.
  Article CAS PubMed Google Scholar
• Amin MA, Haas CS, Zhu K, Mansfield PJ, Kim MJ, Lackowski NP et al. (2005). Migration inhibitory factor upregulates vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 via Src, PI3 kinase, and NFkappaB. Blood 107: 2252–2261.
  Article PubMed Google Scholar
• Amin MA, Volpert OV, Woods JM, Kumar P, Harlow LA, Koch AE . (2003). MIF mediates angiogenesis via mitogen-activated protein kinase and phosphatidylinositol kinase. Circ Res 93: 321–329.
  Article CAS PubMed Google Scholar
• Bando H, Matsumoto G, Bando M, Muta M, Ogawa T, Funata N et al. (2002). Expression of macrophage migration inhibitory factor in human breast cancer: association with nodal spread. JPN J Cancer Res 93: 389–396.
  Article CAS PubMed PubMed Central Google Scholar
• Bech-Otschir D, Seeger M, Dubiel W . (2002). The COP9 signalosome: at the interface between signal transduction and ubiquitin-dependent proteolysis. J Cell Sci 115: 467–473.
  CAS PubMed Google Scholar
• Bernhagen J, Calandra T, Mitchell RA, Martin SB, Tracey KJ, Voelter W et al. (1993). MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365: 756–759.
  Article CAS PubMed Google Scholar
• Brazil DP, Park J, Hemmings BA . (2002). PKB binding proteins. Getting in on the Akt. Cell 111: 293–303.
  Article CAS PubMed Google Scholar
• Burger-Kentischer A, Finkelmeier D, Thiele M, Schmucker J, Geiger G, Tovar GE et al. (2005). Binding of JAB1/CSN5 to MIF is mediated by the MPN domain but is independent of the JAMM motif. FEBS Lett 579: 1693–1701.
  Article CAS PubMed Google Scholar
• Byrne AM, Bouchier-Hayes DJ, Harmey JH . (2005). Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 9: 777–794.
  Article CAS PubMed PubMed Central Google Scholar
• Calandra T, Roger T . (2003). Macrophage migration inhibitory factor: A regulator of innate immunity. Nat Rev Immunol 3: 791–800.
  Article CAS PubMed PubMed Central Google Scholar
• Chamovitz DA, Segal D . (2001). JAB1/CSN5 and the COP9 signalosome. A complex situation. EMBO Rep 2: 96–101.
  Article CAS PubMed PubMed Central Google Scholar
• Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL et al. (2003). Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17: 590–603.
  Article CAS PubMed Google Scholar
• Cheng JQ, Lindsley CW, Cheng GZ, Yang H, Nicosia SV . (2005). The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 24: 7482–7492.
  Article CAS PubMed Google Scholar
• Chesney J, Metz C, Bacher M, Peng T, Meinhardt A, Bucala R . (1999). An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol Med 5: 181–191.
  Article CAS PubMed PubMed Central Google Scholar
• Datta SR, Ranger AM, Lin MZ, Sturgill JF, Ma YC, Cowan CW et al. (2002). Survival factor-mediated BAD phosphorylation raises the mitochondrial threshold for apoptosis. Dev Cell 3: 631–643.
  Article CAS PubMed Google Scholar
• DeGraffenried LA, Fulcher L, Friedrichs WE, Grunwald V, Ray RB, Hidalgo M . (2004). Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann Oncol 15: 1510–1516.
  Article CAS PubMed Google Scholar
• Fingerle-Rowson G, Petrenko O, Metz CN, Forsthuber TG, Mitchell R, Huss R et al. (2003). The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting. Proc Natl Acad Sci USA 100: 9354–9359.
  Article CAS PubMed PubMed Central Google Scholar
• Flieger O, Engling A, Bucala R, Lue H, Nickel W, Bernhagen J . (2003). Regulated secretion of macrophage migration inhibitory factor is mediated by a non-classical pathway involving an ABC transporter. FEBS Lett 551: 78–86.
  Article CAS PubMed Google Scholar
• Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K et al. (2005). Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol 175: 1197–1205.
  Article CAS PubMed Google Scholar
• Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB . (2005). Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4: 988–1004.
  Article CAS PubMed Google Scholar
• Hudson JD, Shoaibi MA, Maestro R, Carnero A, Hannon GJ, Beach DH . (1999). A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med 190: 1375–1382.
  Article CAS PubMed PubMed Central Google Scholar
• Kleemann R, Hausser A, Geiger G, Mischke R, Burger-Kentischer A, Flieger O et al. (2000). Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature 408: 211–216.
  Article CAS PubMed Google Scholar
• Koyasu S . (2003). The role of PI3K in immune cells. Nat Immunol 4: 313–319.
  Article CAS PubMed Google Scholar
• Leng L, Metz CN, Fang YXJ, Donnelly S, Baugh J, Delohery T et al. (2003). MIF signal transduction initiated by binding to CD74. J Exp Med 197: 1467–1476.
  Article CAS PubMed PubMed Central Google Scholar
• Lue H, Kapurniotu A, Fingerle-Rowson G, Roger T, Leng L, Thiele M et al. (2006). Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cell Signal 18: 688–703.
  Article CAS PubMed Google Scholar
• Mitchell RA . (2004). Mechanisms and effectors of MIF-dependent promotion of tumourigenesis. Cell Signal 16: 13–19.
  Article CAS PubMed Google Scholar
• Mitchell RA, Bucala R . (2000). Tumor growth-promoting properties of macrophage migration inhibitory factor. Semin Cancer Biol 10: 359–366.
  Article CAS PubMed Google Scholar
• Mitchell RA, Liao H, Chesney J, Fingerle-Rowson G, Baugh J, David J et al. (2002). Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: Regulatory role in the innate immune response. Proc Natl Acad Sci USA 99: 345–350.
  Article CAS PubMed Google Scholar
• Mitchell RA, Metz CN, Peng T, Bucala R . (1999). Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J Biol Chem 274: 18100–18106.
  Article CAS PubMed Google Scholar
• Morand EF, Leech M, Bernhagen J . (2006). MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis. Nat Rev Drug Discov 5: 399–410.
  Article CAS PubMed Google Scholar
• Nguyen M, Lue H, Kleemann R, Thiele M, Tolle G, Finkelmeier D et al. (2003). The cytokine macrophage migration inhibitory factor (MIF) reduces pro-oxidative stress-induced apoptosis. J Immunol 170: 3337–3347.
  Article CAS PubMed Google Scholar
• Nickel W . (2003). The mystery of nonclassical protein secretion. A current view on cargo proteins and potential export routes. Eur J Biochem 270: 2109–2119.
  Article CAS PubMed Google Scholar
• Nishihira J, Ishibashi T, Fukushima T, Sun B, Sato Y, Todo S . (2003). Macrophage migration inhibitory factor (MIF): Its potential role in tumor growth and tumor-associated angiogenesis. Ann N Y Acad Sci 995: 171–182.
  Article CAS PubMed Google Scholar
• Osaki M, Oshimura M, Ito H . (2004). PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9: 667–676.
  Article CAS PubMed Google Scholar
• Osoegawa A, Yoshino I, Kometani T, Yamaguchi M, Kameyama T, Yohena T et al. (2006). Overexpression of Jun activation domain-binding protein 1 in nonsmall cell lung cancer and its significance in p27 expression and clinical features. Cancer 107: 154–161.
  Article CAS PubMed Google Scholar
• Perren A, Weng LP, Boag AH, Ziebold U, Thakore K, Dahia PL et al. (1999). Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 155: 1253–1260.
  Article CAS PubMed PubMed Central Google Scholar
• Schober A, Bernhagen J, Thiele M, Zeiffer U, Knarren S, Roller M et al. (2004). Stabilization of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient mice. Circulation 109: 380–385.
  Article CAS PubMed Google Scholar
• Shi X, Leng L, Wang T, Wang W, Du X, Li J et al. (2006). CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 25: 595–606.
  Article CAS PubMed PubMed Central Google Scholar
• Shimizu T, Abe R, Nakamura H, Ohkawara A, Suzuki M, Nishihira J . (1999). High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis. Biochem Biophys Res Commun 264: 751–758.
  Article CAS PubMed Google Scholar
• Shiojima I, Walsh K . (2002). Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res 90: 1243–1250.
  Article CAS PubMed Google Scholar
• Song G, Ouyang G, Bao S . (2005). The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 9: 59–71.
  Article CAS PubMed PubMed Central Google Scholar
• Sun H, Bernhagen J, Bucala R, Lolis E . (1996). Crystal structure at 2.6 Å resolution of human macrophage migration inhibitory factor. Proc Natl Acad Sci USA 93: 5191–5196.
  Article CAS PubMed PubMed Central Google Scholar
• Takahashi N, Nishihira J, Sato Y, Kondo M, Ogawa H, Ohshima T et al. (1998). Involvement of macrophage migration inhibitory factor (MIF) in the mechanism of tumor cell growth. Mol Med 4: 707–714.
  Article CAS PubMed PubMed Central Google Scholar
• Tomoda K, Kubota Y, Kato J-Y . (1999). Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1. Nature 398: 160–164.
  Article CAS PubMed Google Scholar
• Veeck J, Niederacher D, An H, Klopocki E, Wiesmann F, Betz B et al. (2006). Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene 25: 3479–3488.
  Article CAS PubMed Google Scholar
• Wetzker R, Bohmer FD . (2003). Transactivation joins multiple tracks to the ERK/MAPK cascade. Nat Rev Mol Cell Biol 4: 651–657.
  Article CAS PubMed Google Scholar
• Wolf DA, Zhou C, Wee S . (2003). The COP9 signalosome: an assembly and maintenance platform for cullin ubiquitin ligases ? Nat Cell Biol 5: 1029–1033.
  Article CAS PubMed Google Scholar
• Zapata JM, Krajewska M, Krajewski S, Huang RP, Takayama S, Wang HG et al. (1998). Expression of multiple apoptosis-regulatory genes in human breast cancer cell lines and primary tumors. Breast Cancer Res Treat 47: 129–140.
  Article CAS PubMed Google Scholar